In addition, clinical trials of CD19 CAR T cells in relapsed/refractory CLL (NCT01029366 and NCT01747486) showed the CAR silencing was associated with CAR T treatment failure, this was caused by abnormal methylation programs of the CAR promoter. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.